Posted by Michael Wonder on 04 Apr 2022
JW Therapeutics announces receipt of breakthrough therapy designation for Carteyva in mantle cell lymphoma in China
3 April 2022 - JW Therapeutics announced that the Center for Drug Evaluation of the National Medical Products Administration of China granted breakthrough therapy designation for Carteyva (relmacabtagene autoleucel) in patients with mantle cell lymphoma.
Carteyva is an anti-CD19 autologous chimeric antigen receptor T cell immunotherapy product independently developed by JW Therapeutics.
